HER-2 in high risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.

Authors

Francesco Sclafani

The Royal Marsden Hospital NHS Foundation Trust

Francesco Sclafani , Amitesh Roy , Ian Chau , Andrew Wotherspoon , Clare Peckitt , Alice Dewdney , Jacqueline Oates , David Cunningham

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 Gastrointestinal Cancers Symposium

bookmark_border

RAS mutations in expert-c, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC).

First Author: Francesco Sclafani

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvant capecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined, high-risk rectal cancer.

First Author: A. Dewdney

insert_chart_outlined

Poster

2022 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2⁺/HER2^– advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study.

First Author: Manish A. Shah

insert_chart_outlined

Poster

2018 Gastrointestinal Cancers Symposium

bookmark_border

INNOVA: A phase II randomized study comparing INterval versus NeOadjuVAnt chemotherapy in magnetic resonance imaging-defined high risk rectal cancer.

First Author: Ramakrishnan Ayloor Seshadri